Before the bell: Futures mixed as Wall Street awaits Paulson's planCitigroup Inc. (NYSE: C)'s Vikram Pandit was brought in to make changes at the struggling bank, and that's exactly what he's doing (or at least trying). After much management changes the past weeks, today the financial services company unveiled a restructuring plan that includes setting up an independent credit-card unit and overhauling consumer banking along geographical, rather than product, lines.
Schering-Plough (NYSE: SGP) stock is dropping nearly 17% and Merck (NYSE: MRK) is dropping over 10% in premarket trading after a study published in the New England Journal of Medicine concluded that doctors should cut their use of cholesterol drugs Vytorin -- a combination of Merck's Zocor and SGP's Zetia -- and Zetia.
Teva Pharmaceutical (NASDAQ: TEVA) is buying Bentley Pharmaceuticals (NYSE: BNT) for $360 million in cash, or $15.02 a share, in a move to expand operations in Spain. Bentley's drug delivery business will be spun off to shareholders prior to the Teva transaction. The purchase price represents a 9% premium to Bentley's closing stock price Friday of $13.74.
Closing Bell: Does The Market Ever Drop? (TSL, PALM, FDX, NKE, TEVA)
Ready for a $2.50 Blueberry Waffle at Starbucks?
EU Is Not the United States of Europe
